Neither the Quantum FIRST trial nor the NCRI AML 18 trial [56] demonstrated a survival benefit to intensive induction chemotherapy with the addition of quizartinib in patients > 60 years with FLT3-mutated AML (Figure 1). Here, FLT3 is linked to acute myeloid leukemia.